Table 1.
Characteristics of participants in the HIV/HCV cohort and BACH/Bone cohort at the time of DXA
| HIV/HCV cohort (n=88) |
BACH/Bone cohort (n=289) |
p value | |
|---|---|---|---|
| Mean age in years (SD) | 51.6 (6.3) | 50.7 (8.6) | 0.31 |
| Race, black (%) | 76 (86.4) | 250 (86.5) | 0.97 |
| Height, cm (SD) | 176.1 (6.5) | 175.2 (6.6) | 0.25 |
| Mean BMI, g/cm2 (SD) | 25.4 (4.8) | 28.2 (4.9) | <0.0001 |
| Mean lean body mass, kg (SD) | 56.2 (8.5) | 59.2 (8.7) | 0.005 |
| Mean fat mass, kg (SD) | 16.56 (8.6) | 21.59 (9.07) | <0.0001 |
| Mean fat ratio (SD) | 1.87 (0.82) | 1.67 (0.48) | 0.03 |
| Smoking status at DXA (%) | 0.16 | ||
| Current | 45 (52.3) | 132 (45.7) | |
| Former | 11 (12.8) | 64 (22.2) | |
| Never | 30 (34.9) | 93 (32.2) | |
| HIV RNA <400 at DXA (%) | 64 (80.0) | ||
| CD4 >200 at DXA (%) | 69 (87.3) | ||
| History of HAART (%) | 73 (84.9) | ||
| Current HAART (%) | 53 (61.6) | ||
| Mean cumulative years on HAART (SD) | 6.08 (3.98) | ||
| Significant liver fibrosis (Metavir ≥2) (%) | 32 (39.0) |
BMI body mass index, DXA dual-energy x-ray absorptiometry, HIV human immunodeficiency virus, RNA ribonucleic acid, HAART highly active antiretroviral therapy